Pharmaceutical Industry in
Plan-Les-Ouates

Stragen Pharma SA

Since 1981 · 101–500 empl.

The core activity of Stragen is the development, manufacture and distribution of pharmaceuticals, particularly niche products for the hospital market, with a focus on the areas of oncology, cardiology, neurology, infectious diseases, antifungals and gynecology.

Addex Pharma SA

Since 2002 · 1–10 empl.

Addex Pharma SA is a clinical-stage pharmaceutical company focused on the development and commercialization of orally available small-molecule allosteric modulators for neurological disorders. Its pipeline includes programs such as dipraglurant (mGlu5 NAM), ADX71149 (mGlu2 PAM) and GABAB PAM candidates targeting indications including substance use disorder and chronic cough.

Epithelix Sàrl

Since 2006 · 11–20 empl.

Epithelix Sàrl develops and supplies in vitro reconstituted human respiratory tissue models and associated culture media, including MucilAir™, SmallAir™ and AlveolAir™. The company also provides laboratory testing services (CRO), such as viral and bacterial infection assays, inhalation toxicity testing, nasal spray evaluation and mucociliary endpoint analyses.

APTISSEN SA

Since 2013 · 51–100 empl.

Aptissen develops and distributes medical products, particularly orthobiological solutions for the treatment of muscle and joint pain. The company's core activities include research, development and marketing of products such as Synolis VA and Cartylis, which are used for tissue regeneration and repair.

SYRHATECH SA

Since 2015 · 11–20 empl.

Syrhatech SA is a Contract Development and Manufacturing Organization (CDMO) specialized in the development and manufacturing of formulations for the cosmetics and pharmaceutical industries. The core activities include research and development (R&D), formulation, manufacturing and analysis of products. The company also offers technology transfer and batch manufacturing for clients.

Vaccine Formulation Institute SA

Since 2020 · 21–50 empl.

The core activity of Vaccine Formulation Institute (VFI) is the development and provision of adjuvants and vaccine formulations for global health. The company supports the vaccine community by providing adjuvants and formulation expertise, supports the development of adjuvanted vaccines up to industrial scale, and helps donors and funders implement vaccine development programs.

CDC LAB SA

Since 2021 · 11–20 empl.

The core activity of CDC LAB SA is the production and distribution of medical cannabis and related products, in particular dried flowers and pharmaceutical active ingredients, which are manufactured under strict quality controls and GMP guidelines. The company also provides consulting services to healthcare professionals and pharmacies regarding the use and application of medical cannabis.

SUBSTIPHARM BIOLOGICS SA

Since 2022 · 11–20 empl.

The core activity of Substipharm is the development, manufacture and marketing of pharmaceuticals, including branded and generic products, as well as biological products and vaccines.

Atheris SA

Since 2012 · 11–20 empl.

Atheris SA is a life sciences company listed on the BioAlps platform as part of the Western Switzerland ecosystem. The accessible page does not provide further details about its products, services, or core activities.

KBI Biopharma SA

Since 2020 · 101–500 empl.·5.0(3)

KBI Biopharma is a Contract Development and Manufacturing Organization (CDMO) specializing in the development and manufacturing of biopharmaceuticals. The company's core activities include: cell line development (mammalian and microbial), process development, analytical development, formulation development, particle and biophysical characterization, mass spectrometry, and clinical and commercial manufacturing of biopharmaceuticals. The company also offers digital solutions and platforms for the development and manufacturing of biopharmaceuticals.

Corsano Health SA

Since 2025 · 21–50 empl.

Corsano Health SA is a MedTech company that develops, manufactures and markets medical‑grade wearable devices and a cloud platform for continuous, real‑time patient monitoring and remote care. Its CardioWatch bracelets measure multiple vital signs (heart rate, respiratory rate, ECG, SpO2, core temperature and cuffless blood pressure), hold CE‑MDR certification and FDA 510(k) clearance, and provide APIs/SDKs and raw data access for clinical research and EMR integration.

NovImmune SA

Since 1998 · 51–100 empl.·5.0(1)

The core activity of NovImmune SA is the development of antibodies, in particular natural bispecific antibodies (κλ-bodies), for the treatment of cancer. The company focuses on the development of therapeutics that specifically target tumor cells by targeting specific molecules such as CD47 and CD28.